Mr. Zimaro is another key strategic addition to the team, and willhave an impact on the corporate strategy and growth opportunities of the company

Vancouver, British Columbia, June 15, 2022 / Globe Newswire / – WellbeingDigital Sciences Inc.  (“Wellbeing” or the “Company”)(NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental health care company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, is very pleased to announce the appointment ofMr. Terry Zimaro to the position of Chief Financial Officer.


Mr. Zimaro is a Chartered Professional Accountant who brings over 20years of public and private company experience in a wide range of finance functions, in particular specializing in high-growth environments, within various industries including psychedelics. He has enabled companies to maximize profitability, operational efficiencies, and enterprise value.


“I am very excited to join Wellbeing Digital Sciences. The Company has a unique value proposition and a strong foundation from which Wellbeing will be able to grow and execute on its vision and mission to fundamentally change the mental health industry through enhanced mental health services and treatments,” stated, Terry Zimaro, CFO.


Wellbeing’s CEO, Najla Guthrie commented "we are pleased to have Terry join our team at an exciting time for the Company. His extensive financial experience, combined with his strong leadership skills will enable him to make an immediate impact on our business. As CFO, Terry is another key strategic addition to our team, and I look forward to working together and seeing his impact on our corporate strategy and growth opportunities.”


About Wellbeing Digital Science

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit


On behalf of:  


Najla Guthrie

Chief Executive Officer  




For further information, please contact:  

Natalie Dolphin

VP of Marketing & Investment Relations  


Twitter: @Wellbeing_IR  


Notice Regarding Forward-Looking Information: 


This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results  expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular,  investor interest in the business and prospects of theCompany.  

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, theCompany disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law.Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.